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ABSTRACT  
   
To date, there have not been any studies in a human population that explore the 
potential of vinegar ingestion in reducing visceral fat, a common yet serious metabolic 
disease risk factor. However, previous research in animal models exhibit promising 
findings, showing that vinegar is effective at reducing visceral fat. This is thought to be 
due to the activation of AMPK (adenosine monophosphate protein kinase) by acetic acid, 
the active ingredient in vinegar. The purpose of this study was to identify if this 
potentially groundbreaking relationship exists in human subjects. Healthy, nonsmoking, 
sedentary adults between the ages 18-45 y and a waist circumference measurement 
greater than or equal to 33 inches for women and 38 inches for men were recruited for 
this study. Twenty-three participants completed this 8-week, parallel arm, randomized 
control trial that tested the efficacy of red wine vinegar consumption (2 tablespoons red 
wine vinegar, twice per day, before a meal; providing 3.6 g acetic acid) against a placebo 
(1 apple cider vinegar pill, twice per day, before a meal; providing 0.0225 g acetic acid) 
for 8 weeks. Participants were randomized into either the vinegar (VIN) or control (CON) 
group after being stratified by age, gender, waist circumference, and weight. Results 
found that the VIN group experienced a 2% decrease in visceral fat (cm3, quantified by a 
DXA scan), but this change did not differ significantly from that of the CON group 
(p=0.256). The VIN group also experienced a slight decrease in insulin compared to the 
CON group, but this change was not significantly different than the control change 
(p=0.125). However, the change in HOMA-IR trended downward in the VIN group (-
16%) as compared to the CON group (+9%) (p=0.079) with a large effect size, 0.153. 
Other parameters did not show statistically significant results between the groups. Further 
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research is indicated in order to examine the potential of vinegar to reduce visceral fat.
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CHAPTER 1 
INTRODUCTION 
Nearly 35% of adults and 50% of elderly Americans have been found to have 
metabolic syndrome, a concerning cluster of health conditions that include obesity, high 
blood pressure, an “at-risk” waist circumference (over 40 inches for men and 35 inches 
for women), and dyslipidemia (Han and Lean, 2016). Presence of significant visceral fat 
has been linked to the development of metabolic syndrome.  Current research indicates 
that visceral fat is detrimental to overall health, and the implications go far beyond waist 
size. Many studies have validated this statement, and there is a need for more research on 
how to decrease this increasingly prevalent health risk. 
 Vinegar ingestion has historically been widely used to alleviate a variety of 
ailments, from improving blood glucose levels to reducing systolic blood pressure 
(Johnston and Gaas, 2006). Current research is beginning to further explore potential 
benefits of vinegar. Visceral fat, defined as fat that surrounds the organs within the 
abdominal cavity, has been linked to various metabolic consequences such as insulin 
resistance, elevated fasting blood glucose levels, systemic inflammation, hypertension, 
and elevated triglycerides (Fox et al., 2007; Wilcox 2005; Frayn 2000; Johnston and 
Gaas, 2006). Seeing as vinegar has proven beneficial in reducing blood glucose and 
blood pressure in past studies, interest has increased in studying the potential of vinegar 
in reducing visceral fat. There are a multitude benefits involving visceral fat reduction, 
such as improved insulin sensitivity, lower levels of inflammation, lower waist 
circumference, and increased sensitivity to leptin, a hormone that plays a role in fat 
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storage regulation and satiety (Sanguankeo et al., 2016; Fontana et al., 2007; Matsuzawa, 
1991; Lee et al., 2008). 
 Multiple studies have identified the effect of vinegar on various health outcomes. 
More importantly, acetic acid metabolism has shown promising effects on fat oxidation. 
A recent study involving a rat model found that vinegar ingestion in the presence of a 
high-fat diet attenuates adiposity (Ok et al., 2013). The mechanism behind the findings 
involves an enzyme called adenosine monophosphate-activated protein kinase (AMPK) 
(Ok et al., 2013). When vinegar is consumed, it increases the phosphorylation of AMPK 
(Ok et al., 2013). This causes changes in mRNA, changing and increasing the expression 
of various hormones and enzymes that involve adipose tissue (Ok et al., 2013). Because 
of AMPK, lipolysis in adipose tissue and fatty acid oxidation in the liver is stimulated, 
and fatty acid synthesis is suppressed (Ok et al., 2013). The results of this study showed 
that even with a diet high in fat, vinegar ingestion resulted in increased levels of AMPK 
and decreased levels of body weight, overall fat mass, hepatic triglycerides, and plasma 
triglycerides (Ok et al., 2013). This study illustrates that vinegar has systemic benefits in 
animals, and there is a need for a study to identify if the benefits are similar in humans. 
To date, there has not been a study that directly measures vinegar consumption 
and visceral fat loss in human subjects. Many studies have shown the clear link between 
vinegar ingestion and a decrease in blood glucose levels and other parameters, but there 
is a need for identification of this other possible relationship.  
 A study identifying this potential link is important because it will help identify an 
affordable and widely available method of decreasing visceral fat, and in turn, metabolic 
disease risk. 
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Purpose of Study 
The purpose of this study is to test the potential ability of red wine vinegar to 
significantly decrease visceral fat in healthy adults with “central obesity”. During the 8-
week trial, participants will either consume a vinegar drink or low-dose vinegar pill twice 
per day. 
Research Aim and Hypothesis 
H1 Daily red wine vinegar consumption will be associated with loss in visceral fat (as 
measured by DXA) after 8 weeks compared to the placebo treatment (low-vinegar pill) in 
a group of healthy adults with “central obesity”. 
H2 Daily red wine vinegar consumption will be associated with a decrease in abdominal 
circumference after 8 weeks compared to the placebo treatment (low-vinegar pill) in a 
group of healthy adults with “central obesity”. 
HO Daily red wine vinegar consumption is not associated with loss in visceral fat or 
abdominal circumference after 8 weeks compared to the placebo treatment. 
Definition of Terms  
 Adipocytokine – a protein secreted by adipose tissue that is capable of cell 
signaling and can mediate immunity and inflammation  
 Adiponectin – a hormone that helps regulate fatty acid oxidation and glucose use, 
inversely correlated with body fat percentage 
 Acetic Acid – the main component of vinegar that is classified as a weak acid 
with the chemical form CH3COOH. The average acid content of commercially 
available vinegar is 5% 
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 Body Mass Index (BMI) – a screening tool that compares weight to height in 
effort to predict body composition 
Underweight:  <18.5 kg/m2 
Normal weight: 18.5-24.9 kg/m2 
Overweight: 25-29.9 kg/m2 
Obese: >30 kg/m2 
 Central Obesity – characterized by having a large amount of fat in the abdominal 
area, also classified as having an  “apple” or “android” body shape 
 Dual-Energy X-Ray Absorptiometry (DXA) – a type of x-ray technology that 
utilizes two different-energy x-ray beams to evaluate bone density or body 
composition 
 Fermentation – a metabolic process that converts sugar to acids or alcohols 
mediated by yeast, bacteria, or other microorganisms 
 Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) – a 
calculation that estimates insulin sensitivity; calculated as fasting glucose 
(mg/dL)*fasting insulin (uU/mL)/405 
 Leptin – a hormone secreted by adipocytes, known as the “satiety hormone”  
 Metabolic Syndrome – a cluster of risk factors (central obesity, high 
triglycerides, low HDL cholesterol, high blood pressure, and/or high fasting blood 
sugar) that increases risk for stroke, diabetes, and/or coronary heart disease 
 Obesity – a disease characterized by excessive amounts of adipose tissue and a 
BMI of 30 or higher 
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 Visceral Fat – also known as inter-abdominal fat; this type of fat is located in the 
abdominal cavity and is typically packed between organs  
Delimitations and Limitations 
Delimitations: 
 Healthy, nonsmoking adults between the ages 18-45 will be recruited for this 
study. Men must have a waist circumference greater than or equal to 38 inches 
and women must have a waist circumference greater than or equal to 33 
inches. Participants must be free from any known chronic disease and women 
may not be pregnant. Results of this study may not be applicable to other age 
groups or disease states. 
Limitations: 
 The drinks used in the experimental group were clearly labeled that they 
contained red wine vinegar; participants may try to “guess” why they are 
drinking it, which may cause bias. 
 Participants were asked to not change their eating or exercise habits during the 
time of the study; however, adherence to this request cannot be guaranteed. 
 Participants were also encouraged to follow the provided directions for their 
supplement consumption; adherence to this request cannot be guaranteed.  
 Nausea was a common side effect among VIN participants, which may have 
reduced dietary intake at any point in the intervention. However, there were 
not any significant changes in weight observed.  
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CHAPTER 2 
REVIEW OF THE LITERATURE 
Vinegar Production 
Any fermentable source of carbohydrates can be used to make vinegar (Johnston 
and Gaas, 2006). Vinegar (from vin aigre, French for “sour wine”) production first begins 
with yeast fermenting the natural sugar found in the source, converting it to alcohol 
(Johnston and Gaas, 2006). The alcohol is then converted to acetic acid by the bacteria 
Acetobacter aceti (“Vinegars and Acetic Acid Bacteria”, 2005). Acetic acid is a volatile 
organic acid and is recognized as the active ingredient in vinegar, responsible for the 
distinctively sharp aroma and flavor (“Vinegars and Acetic Acid Bacteria”, 2005). 
Acetobacter aceti is a member of the Acetobacteriaceae family, which stain either as 
Gram negative or variable, are oxidase negative, and function as obligate aerobes (Budak 
et al., 2014). The optimum pH for acetic acid production is 5.0-6.5, with a temperature 
range of 25-30 degrees Celsius or 77-86 degrees Fahrenheit (Budak et al., 2014). There 
are two methods of production used to produce vinegar; time being the main difference 
between the methods. Traditional wine vinegars are produced using the slow method of 
production. This process allows the Acetobacter culture to slowly grow on the liquid, so 
fermentation occurs over the course of a few weeks to months depending on the desired 
outcome (Johnston and Gaas, 2006). This traditional method has the vinegar produced in 
a barrel, where it is filled to 2/3 capacity to allow the culture of bacteria to mix with the 
liquid and outside air (Mas et al., 2014). This method is also known as “surface culture” 
(Mas et al., 2014). A more modern method of traditional production is called the 
“Orleans method”, which includes side holes in the barrel for air circulation and a funnel 
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at the base of the barrel for wine to be poured in (Mas et al., 2014). The funnel also helps 
the “mother” of vinegar to not be disturbed. The mother is a biofilm that is formed by 
acetic acid bacteria and yeast, and is typically produced by a considerably long process of 
fermentation (Mas et al., 2014; Johnston and Gaas, 2006). Many believe that the mother 
has various health benefits, such as improving immunity and healing sunburns, but there 
is no scientific research solely on the mother to validate these claims.  
For quicker, commercial preparation, the liquid is oxygenated and the Acetobacter 
culture is quickly introduced to allow accelerated fermentation (Johnston and Gaas, 
2006).  Industrial vinegars can typically be manufactured in as short as one day (Budak et 
al., 2014). However, the vinegars produced by the traditional methods are considered to 
be of higher quality for a variety of reasons (Mas et al., 2014). Quality is influenced by 
the substrate used to create the vinegar, such as wine or fruit (Mas et al., 2014). A higher 
quality substrate will produce a higher quality vinegar. The interaction between the wood 
of the barrels and the vinegar also increases overall quality, because it helps influence the 
metabolism of the bacteria and the overall aging process (Mas et al., 2014). Other 
compounds are also produced through the traditional methods, such as esters and 
byproducts of oxidation reactions (Mas et al., 2014). 
Depending on the carbohydrate source chosen, vinegar may also include other 
organic acids such as malic or citric acid, polyphenolic acids such as caffeic or galic acid, 
or various vitamins and minerals (Natera et al., 2003).  Red wine vinegar contains 
varying amounts citric, formic, lactic, malic, succinic, and tartaric acids in addition to 
acetic acid (Natera et al., 2003). However, no matter the carbohydrate source chosen or 
other acids present, the final product must contain at least 4% acetic acid to officially be 
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classified as vinegar (Budak et al., 2014). Typical vinegar products contain between 4-
15% acetic acid (Johnston and Gaas, 2006).  Common commercially available vinegars 
include red wine, apple cider, raspberry, balsamic, and rice vinegar. Kombucha is also 
another increasingly-popular source of acetic acid, produced from a symbiotic culture of 
fermented Acetobacter and black and/or green tea (Bhattacharya et al., 2016). 
Types of Vinegar 
Table 1: Types of Vinegar 
Types of Vinegar (Adapted from Budak et al., 2014) 
Type Main country of 
production 
Acetic acid 
content 
Bacterial species Notable 
properties 
Apple cider 
vinegar 
Worldwide  5-6%  Acetobacter 
pasteurianus, aceti 
and intermedius 
Gold color, 
made from 
pressed 
apples, 
sweeter flavor 
than other 
vinegars 
Balsamic 
vinegar 
Italy 4-10% Acetobacter 
pasteurianus, 
Gluconacetobacter 
hansenii, 
Gluconacetobacter 
Dark brown 
color, made 
from 
Trebbiano 
grapes, tart  
  9 
xylinus and strong 
flavor 
Distilled/white 
vinegar 
Worldwide 5-8% Acetobacter 
pomorum, 
Acetobacter 
obeidiens, 
Gluconacetobacter 
entanii 
Made from 
distilled 
alcohol, malt, 
or corn, often 
used in foods 
like ketchup 
or salad 
dressings, 
may be used 
for cleaning 
Kombucha Japan, United 
States 
5-7% Acetobacter 
xylinum, 
Gluconacetobacter 
xylinus, 
Gluconacetobacter 
kombuchae 
Made from 
fermented 
black and/or 
green tea, is a 
rich source of 
probiotics, 
symbiotic 
culture of 
bacteria and 
yeast, 
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contains B 
vitamins 
Red wine 
vinegar 
Worldwide 4-6% Acetobacter 
pasteurianus, 
Gluconacetobacter 
europaeus 
Rich red 
color, robust 
flavor, made 
from red 
wines like 
Merlot  
White wine 
vinegar 
Italy, Turkey 5-6% Gluconacetobacter 
europaeus, 
Gluconacetobacter 
xylinus 
Typically 
made from 
Pinot Grigio, 
slightly sweet 
flavor 
 
 Typical and Historical Medicinal Uses of Vinegar 
 Vinegar has been frequently used to ameliorate various ailments since around the 
year 5000 B.C. (Budak et al., 2014). Hippocrates used vinegar for wound management 
and healing of sores; while 10th century forensic medicine pioneer Sung Tse used it to 
avoid infection while performing autopsies (Johnston and Gaas, 2006). Early 18th century 
medical practitioners often used vinegar as a “cure-all” for ailments such as edema, fever, 
croup, stomachache, and poison ivy (Budak et al., 2014).  Those who prefer natural 
methods of healing often use vinegar to help treat common issues such as head lice, nail 
fungus, and ear infections (Rutala et al, 2000). Vinegar was also widely used in food 
  11 
preparation and preservation, but current research is inconclusive in deciding if acetic 
acid is effective in reducing growth of foodborne illness-producing pathogens (Johnston 
and Gaas, 2006; Kilonzo-Nthenge et al., 2006).  It is thought that the acids found in the 
vinegar pass into the cell membranes of pathogens induce bacterial cell death, but it is not 
always effective in reducing amounts of bacteria for safe consumption due to potential 
inconsistencies temperature and exposure time (Budak et al., 2014). However, it has been 
found that acetic acid is the most lethal acid to Escherichia coli O157:H7 (Entani et al, 
1998; Ryu et al., 1999). One study found that using rice vinegar (5% acetic acid) on 
lettuce inoculated with Escherichia coli O157:H7 for 5 minutes at 77 degrees Fahrenheit 
resulted in a 3 log reduction in the bacterial population (Chang and Fang, 2007). Another 
study looked to determine the effectiveness of vinegar in reducing amounts of pathogens 
on vegetables (Sengun and Karapinar, 2004). This study created a mixture containing 
4.03% acetic acid and lemon juice, and tested it on carrots that were positive for 
Salmonella typhimurium (Sengun and Karapinar, 2004). The mixture was applied for 
different exposure times, ranging from 0-60 minutes (Sengun and Karapinar, 2004). It 
was found that the 60 minute treatment period was the most effective at reducing 
amounts of the bacteria (Sengun and Karapinar, 2004).  Another study focused on 
comparing various methods for cleansing produce (Kilonzo-Nthenge et al., 2006). 
Apples, tomatoes, lettuce, and broccoli were all inoculated with Listeria innocua and 
underwent various cleaning methods: soaked for 2 minutes in tap water, rinsed in Veggie 
Wash solution, rinsed in 5% vinegar solution, and rinsed in 13% lemon solution 
(Kilonzo-Nthenge et al., 2006). The produce was then either rinsed under running tap 
water, brushed under running tap water, rinsed and rubbed under running tap water, or 
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wiped with a paper towel (Kilonzo-Nthenge et al., 2006). It was found that brushing the 
produce under running water significantly lowered the amount of bacteria in the produce, 
but soaking the produce in the vinegar or lemon solutions were not significantly different 
in levels of bacteria than the produce just soaking in tap water (p>0.05) (Kilonzo-
Nthenge et al., 2006). More research is warranted to fully discover vinegar’s 
antimicrobial effects and efficacy of using vinegar as cleaning agent. 
Fast-forward to current times, vinegar is increasing in popularity as an affordable 
remedy that helps manage  blood glucose levels, improve waking blood sugar levels in 
type 2 diabetics, delay gastric emptying, remedy basic ear infections, and has even shown 
to exhibit antitumor activity (Johnston and Gaas, 2006; Khan and Khan, 2015).  
Vinegar as a Functional Food 
There have been multiple studies to show that vinegar exhibits properties that 
classify it as a functional food. A “functional food” is a food that provides health benefits 
beyond essential vitamins and minerals and is also often commonly referred to as a 
“nutraceutical” (Hasler, 2002). Vinegar has been shown to alter glycemic response after 
meal ingestion (Johnston and Gaas, 2006; Johnston and Buller, 2004; Brighenti et al., 
1995; Liljeberg and Bjorck, 1998; Mitrou et al., 2015), delay gastric emptying 
(Hlebowicz et al., 2007; Liljeberg and Bjorck, 1998), and function as an anti-infective 
(Johnston and Gaas, 2006; Mota et al., 2015).  It has been found that the mechanisms 
responsible for the “nutraceutical” effects of vinegar are due to acetic acid, the active 
ingredient in vinegar.  
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Acetic Acid 
 Acetic acid, also known as vinegar acid or ethanoic acid, is the active ingredient 
in vinegar and is largely responsible for the variety of health benefits that result from 
vinegar ingestion (“Acetic Acid”, 2016). The molecular formula for acetic acid is 
CH3COOH (“Acetic Acid”, 2016). It is classified as a carboxylic acid and has a hydroxyl 
and acetyl group (“Acetic Acid”, 2016). Acetic acid is present in commercially available 
vinegar, concentrated at values between 4-15% (Ogawa et al., 2000).  Acetic acid is 
produced via Acetobacter aceti though the process of fermentation (Ogawa et al., 2000).  
Acetic acid can also be produced via the human digestion process. When indigestible 
carbohydrates, typically insoluble fiber such as bran or psyllium, are consumed, they are 
fermented by the microbiome present in the large intestine and produce short chain fatty 
acids, one being acetate, the salt form of acetic acid (Ogawa et al., 2000). The effects of 
acetic acid on the body and metabolism are still being explored within the literature; but a 
recent study has found that acetate improves glucose tolerance (Yamashita et al., 2007). 
This study was conducted on a group of obese, type 2 diabetic rats that were orally 
injected with 5.2mg/kg acetate (Yamashita et al., 2007). It was found that the acetate 
treatment resulted in a reduction in lipid accumulation in adipose tissue, reduced hepatic 
adiposity, and improved glucose tolerance (Yamashita et al., 2007). It was found via 
Northern blotting analysis that in the liver of the rats, transcription factors of lipogenic 
genes in the liver were decreased (Yamashita et al., 2007). Upon further analysis, acetate 
has an inhibitory effect on carbohydrate-responsive element-binding protein (ChREBP) 
activity in the liver (Yamashita et al., 2007). ChREBP is a transcription factor that 
facilitates multiple genes that are responsible for converting glucose to fatty acids in the 
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liver, thus explaining the noted decrease in hepatic adiposity (Yamashita et al., 2007). 
Another study involving mice fed inulin, a type of easily fermented fiber, gained less 
weight, consumed less food, and increased total short chain fatty acid colonic 
concentrations in comparison to the rats fed poorly fermentable fiber (Yamashita et al., 
2007). Acetate was found to be the most abundant SCFA in the inulin-fed rats post 
intervention (Yamashita et al., 2007). It was also found that the acetate is largely 
responsible for appetite regulation, because it encourages the release of the hormones 
peptide YY and glucagon-like peptide-1 (Yamashita et al., 2007). These hormones are 
responsible for regulating hunger and satiety, and modulate insulin secretion from the 
pancreas, respectively (Yamashita et al., 2007).  
Antiglycemic Properties of Vinegar 
Various studies have verified that vinegar exhibits antiglycemic properties and 
improves insulin response. One study by Johnston and Buller explored the action of 
vinegar in reducing glycemia after a high-carbohydrate meal. A total of 29 participants 
with varying degrees of insulin response consumed either a placebo drink or vinegar 
before consuming the test meal consisting of a white bagel and orange juice (Johnston 
and Buller, 2004). At 60 minutes post-ingestion, the vinegar ingestion raised the total 
insulin sensitivity by 34% (p=0.01) in those who were insulin resistant (Johnston and 
Buller, 2004). Type 2 diabetics experienced a 19% increase in insulin sensitivity 
(p=0.07). Postprandial changes in blood glucose were also significantly reduced 
(Johnston and Buller, 2004). Acetic acid can suppress disaccharidase activity, helping to 
dull the spike in glucose that commonly occurs after a meal (Johnston and Buller, 2004; 
Ogawa et al., 2000). Similar to the activity of Metformin, a commonly prescribed drug 
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that helps control blood glucose levels, vinegar raises the concentration of glucose-6-
phosphate activity in skeletal muscle (Johnston and Buller, 2004). Glucose-6-phosphate 
is a form of glucose that is phosphorylated on the 6th carbon (Villar-Palasi and Guinovart, 
1997). It has been found that elevated levels of glucose-6-phosphate helps activate 
glycogen synthase in muscle, liver, and adipose tissue (Villar-Palasi and Guinovart, 
1997). Glucose-6-phosphate also responds to elevated blood glucose concentrations, and 
increases its presence intracellularly, thus activating glycogen synthase (Villar-Palasi and 
Guinovart, 1997). Glucose-6-phosphate is also involved in the detoxification of radicals 
by regulating glutathione peroxidase activity, assist in cholesterol and triglyceride 
synthesis, and influence the pentose phosphate cycle, which produces NADPH 
(nicotinamide adenine dinucleotide phosphate) for anabolic reactions such as lipid and 
nucleic acid synthesis (Schmitz et al., 1993). One study involving a group of rats 
analyzed the effect of acetic acid on glycogen repletion activity. The rats were given a 
standard diet for 6 days, and then were deprived of food for 15 hours in effort to deplete 
their glycogen stores (Fushimi et al., 2001). They were then either given a diet containing 
0g, 0.1g, 0.2g, or 0.4g acetic acid (Fushimi et al., 2001). It was found that the 0.2g acetic 
acid group had higher concentrations of glucose-6-phosphate in comparison to the control 
group, as well as higher concentrations of glycogen in the liver and gastrocnemius muscle 
(Fushimi et al., 2001). The researchers hypothesized that acetic acid inactivates 
glycolysis and assists in activating gluconeogenesis by suppressing phosphofructokinase-
1 activity, which is one of the key regulatory enzymes needed for glycolysis (Fushimi et 
al., 2001). Studies involving human subjects are warranted to further these findings, but 
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this study involving a rat model is promising in deciphering the exact mechanism behind 
glucose-6-phosphate and acetic acid. 
Another study explored vinegar consumption and the potential effects on blood 
glucose. In a group of five healthy subjects, blood glucose responses were analyzed after 
consuming a salad with a vinegar dressing and 50g of carbohydrates from white bread 
(Brighenti, et al., 1995). Postprandial glucose levels were reduced by 31.4% (p=.020) 
(Brighenti, et al., 1995). Although the sample size was small, this study illustrated that 
vinegar ingestion, even in the form of salad dressing, was followed by a lower glycemic 
response after a high carbohydrate load. 
Vinegar may also be useful in delaying gastric emptying. A study involving 10 
healthy adults with normal BMIs were recruited to test vinegar’s potential role in 
modulating gastric emptying times (Lilijeberg and Bjorck, 1998). Using paracetamol 
(acetaminophen) as an indicator of gastric emptying, participants in both groups 
consumed a white bread meal and then had their glucose, insulin, and paracetamol levels 
analyzed (Lilijeberg and Bjorck, 1998). The experimental group also consumed vinegar 
along with their meal (Lilijeberg and Bjorck, 1998). It was found that the acetic acid from 
the vinegar reduced postprandial insulin and glucose response after the meal; further 
analysis of paracetamol levels suggested that delayed gastric emptying rates were 
responsible for the reduction in postprandial values (Lilijeberg and Bjorck, 1998). 
However, vinegar consumption is contraindicated in type 1 diabetics, particularly those 
with gastroparesis (Hlebowicz et al., 2007).  It can further slow gastric emptying times, 
which is disadvantageous for maintaining proper insulin and glycemic control 
(Hlebowicz et al., 2007).  
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Antihypertensive Properties of Vinegar 
Vinegar has also been found to have antihypertensive properties. A recent study 
using a spontaneously hypertensive rat model assigned the rats to orally consume either 
vinegar, concentrated acetic acid, or distilled water for 8 weeks (Na et al., 2016). It was 
found that vinegar and acetic acid consumption both decreased blood pressure (Na et al., 
2016). Further analysis found that vinegar and acetic acid decrease total serum levels of 
angiotensin-converting enzyme (ACE) and renin, two hormones responsible for increases 
in blood pressure (Na et al., 2016). Total AMP/ATP ratios were found to be elevated, 
which increases the amount of energy produced and used by cells (Na et al., 2016). 
Although this study was done in rats instead of humans, it still exhibited promising 
cardiovascular effects due to acetic acid and vinegar consumption.  
Another study by Kondo and colleagues reported similar findings. Spontaneously 
hypertensive rats were fed a standard diet and were supplemented with a vinegar/acetic 
acid solution or deionized water for 6 weeks (Kondo et al., 2001). Reductions in systolic 
blood pressure and renin and aldosterone concentrations were observed in the rats treated 
with the vinegar/acetic acid diet (Kondo et al., 2001). Antihypertensive effects in 
response to vinegar consumption have yet not been studied in human participants, but 
animal results are promising. 
Antitumor Properties of Vinegar 
The antitumor properties of vinegar are still being investigated, but current studies 
have illustrated a significant potential. One study tested the effects of ethyl acetate extract 
from a Japanese traditional vinegar made from unpolished rice, called “Kurosu” on the 
proliferation of cancer cells (Nanda et al., 2004). Researchers included cancer cells from 
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colon adenocarcinoma, breast adenocarcinoma, bladder carcinoma, prostate carcinoma, 
and lung carcinoma (Nanda et al., 2004).The extract was most effective against the colon 
adenocarcinoma, showing up to 62% inhibition against cell proliferation (Nanda et al., 
2004). The results of this study suggest that the extract induces cell apoptosis in these 
cells, indicating that this treatment may prove effective in reducing or even preventing 
the spread of colon cancer cells (Nanda et al., 2004).  
Another study discovered similar findings involving colon cancer cells, but 
looked at anticarcinogenic potential all of the short chain fatty acids, particularly when 
they are produced via fermentation of dietary fiber (Fu et al., 2004). It has been 
hypothesized that the short chain fatty acids (SCFAs) can help prevent carcinogenesis of 
colon cells because they help maintain colonocyte differentiation (Fu et al., 2004). This 
study focused on a specific phenotype of colonic adenocarcinoma cells called Caco-2 (Fu 
et al., 2004). The cells were treated with 10mmol of each SCFAs, and it was found that 
all of the SCFAs altered the phenotype of Caco-2, prolonging cell doubling time, 
inhibiting cell motility, and promoted the expression of a differentiation marker (Fu et al., 
2004). In conclusion, SCFAs produced via fermentation of dietary fiber may be 
protective against colon cancer (Fu et al., 2004).  
Safety and Potential Risks of Vinegar Consumption 
There are very few incidences in the literature reported involving adverse 
consequences resulting from vinegar ingestion. One particular case involved a 39-year 
old woman who tried to dissolve a crab shell stuck in her throat by drinking one 
tablespoon of white vinegar, based on a folklore myth (Chung, 2002). She experienced 
vasovagal syncope and laryngospasm, and an endoscopy revealed a second-degree 
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caustic injury to the lining of the esophagus (Chung, 2002). Unintentional aspiration of 
vinegar was thought to provoke the symptoms, which resolved spontaneously (Chung, 
2002).   
Another incident regarding vinegar ingestion involves a 28-year-old woman who 
suffered from hypokalemia, speculatively due to prolonged, daily apple cider vinegar 
consumption (Lhotta et al., 1998). However, both incidents appear to be isolated as no 
other similar adverse reactions have been reported. As the popularity of vinegar ingestion 
increases, more research is warranted to identify other possible risks.  
AMPK Activation and Application 
The expression of the adenosine monophosphate-activated protein kinase 
(AMPK) has emerged within the literature as an important regulator of metabolism and 
energy balance (Viollet et al., 2010). AMPK is an obligate heterotrimer that contains a 
catalytic subunit (α), and two regulatory subunits (β and ) (Mihaylova and Shaw, 2012). 
It is known to phosphorylate and inactivate acetyl-CoA carboxylase-1 and 3-hydroxy-3-
methylglutaryl-CoA reductase, two enzymes that regulate sterol and fatty acid synthesis 
within mammals (Hardie, 2013). It functions as the “metabolic master switch” that, when 
activated, adapts to changes in environment (starvation vs. overfeeding) and 
phosphorylates key proteins that are involved in various metabolic pathways, such as 
lipogenesis, triglyceride synthesis, hepatic ketogenesis, insulin secretion, and glucose 
uptake (Winder and Hardie, 1999). It is a highly conserved and keen sensor of adenosine 
nucleotide levels within the cell (Mihaylova and Shaw, 2012). It can sense changes 
within the body that stress or depress overall cell energy status, such as hypoglycemia, 
hypoxia, or muscle contraction (Hardie, 2013). When ATP production within the cell 
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decreases, AMPK is able to promote catabolic pathways in order to make more ATP 
(Mihaylova and Shaw, 2012). It has been found that Threonine-172, located within the 
catalytic subunit, is the major site of phosphorylation and activation for AMPK 
(Mihaylova and Shaw, 2012). A kinase called LKB1 is what mediates this 
phosphorylation, which is a tumor suppressor gene (Mihaylova and Shaw, 2012). It is 
suggested that AMPK may play a role in tumor suppression due to the presence of LKB1, 
but more research is needed (Mihaylova and Shaw, 2012). LKB1 also responsible for 
phosphorylating and activating twelve other kinases related to AMPK (Mihaylova and 
Shaw, 2012).  
Defects in AMPK activation and a decrease in overall AMPK activity were found 
in those with sedentary lifestyles or type 2 diabetes (Winder and Hardie, 1999). 
Conversely, AMPK activation is amplified by exercise; illustrated by the fact that AMPK 
is activated in skeletal muscle during muscle contraction (Winder and Hardie, 1999).  
AMPK also encourages glucose uptake in skeletal muscle by upregulating GLUT4, a 
glucose transporter (Hardie, 2013). Recent data has shown that in a rat model, low 
activation frequencies of AMPK have a strong correlation with metabolic dysfunctions, 
such as obesity and insulin resistance (Viollet et al., 2010). A study by Kraegen and 
colleagues found that frequent hyperglycemia reduces AMPK activation in the liver and 
muscle (Kraegen et al., 2005). This study involved infusing nondiabetic rats with glucose 
for a constant 5 hours in order to induce insulin resistance (Kraegen et al., 2005). Muscle 
analysis found that insulin resistance due to a constant state of hyperglycemia in the 
muscle resulted in a 50% decrease in AMPK (Kraegen et al., 2005). This concluded that a 
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steady influx of glucose resulted in temporary insulin resistance, which in turn decreased 
AMPK activation (Kraegen et al., 2005).  
A recent study in bovine hepatocytes illustrated how acetic acid can activate 
AMPK. Ruminant animals typically consume mainly cellulose and starch as their source 
of carbohydrates (Li et al., 2013). The microbiome of bovines converts cellulose and 
starch to short chain fatty acids (SCFAs), one importantly being acetic acid (Li et al., 
2013). Nearly 70-75% of SCFAs produced from bovine digestion are acetic acid, making 
the average acetate concentration in cattle nearly a dozen times higher than the 
concentration in humans (Li et al., 2013). This study isolated bovine hepatocytes and 
treated half with 3.6mM neutralized acetic acid for 24 hours and the other half with 
1.8mM acetate (Li et al., 2013). After harvesting the cells, it was found that the cells 
treated with 3.6mM showed higher AMPK activity than the cells treated with the smaller 
amount (Li et al., 2013). This study illustrates the important relationship between acetic 
acid and AMPK activation, and further studies are needed to solidify these findings. 
Resveratrol, a polyphenol that is found in red grapes, has also been shown to 
activate AMPK and function similarly to Metformin, a commonly prescribed drug for 
type 2 diabetes that works by suppressing hepatic gluconeogenesis (Mihaylova and Shaw, 
2012). Resveratrol has been found to activate AMPK by inhibiting the F1F0 
mitochondrial ATPase, which helps catalyze ATP synthesis, in a rat model (Mihaylova 
and Shaw, 2012). It has been estimated that red wine contains between 0.2-5.8mg/L 
resveratrol depending on the type of grapes chosen (Prasad, 2012). 
A study by Ok and colleagues found another important metabolic influence of 
AMPK. Sprague-Dawley rats were fed a high-fat diet in order to induce obesity. They 
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were then divided into 5 groups; half of the groups were supplemented with pomegranate 
vinegar, providing 2.16g acetic acid per day (Ok et al., 2013). Liver, muscle, and adipose 
tissue were then analyzed and found that the rats supplemented with pomegranate vinegar 
had an increased rate of AMPK activation (Ok et al., 2013). This resulted in an increase 
in hormone-sensitive lipase and a reduction in fat mass, total body weight, plasma and 
hepatic triglycerides (Ok et al., 2013). This study illustrates the effect of vinegar 
consumption on AMPK activation, generating a need for more research, particularly in 
humans. 
Visceral Fat 
 Definition 
 Due to the increasing prevalence of obesity and obesity-related illnesses in 
America, there have been many efforts to increase the understanding of the clinical 
importance and pathogenic mechanisms of visceral fat. Visceral fat is adipose tissue that 
is stored around and between the intra-abdominal organs and is known to be hormonally 
active (Shuster, et al., 2012). Having high amounts of visceral fat is known as “central 
obesity” and is characterized by having an “android” or “apple” body shape (Shuster et 
al., 2012). It has been found to influence both pathological and normal processes in the 
human body, and is closely associated with cardiovascular disease, neoplastic diseases, 
and metabolic syndrome (Shuster et al., 2012). Visceral fat is correlated with frequent 
production of inflammatory cytokines, a lower rate of lipolysis, and a higher amount of 
circulating triglycerides, which illustrates some of the many ways how it can influence 
the development and progression of a variety of metabolic diseases (Hansen et al., 2006).  
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 Inflammation is considered a significant consequence of visceral fat for a variety 
of reasons. It has been found that when there is an “inappropriate expansion” of 
adipocytes, macrophages and other inflammatory cells flood the tissues (Gustafson and 
Smith, 2015). Pre-adipose cells can act like macrophages under appropriate conditions, 
and can even influence the transcription factor PPAR, which helps regulate insulin-
sensitive adipose cells (Gustafson and Smith, 2015). PPAR is a member of the 
peroxisome proliferator-activated receptor, which is needed for activation of genes that 
modulate adipogenesis and adipose cell function (Gustafson and Smith, 2015). It also 
influences the GLUT4 glucose transporter, adiponectin, leptin, and regulates lipid 
storage, metabolism, and insulin sensitivity for the body (Gustafson and Smith, 
2015).Those who have mutations in PPAR have been found to have insulin resistance 
and an almost 8-fold increase in developing type 2 diabetes (Gustafson and Smith, 2015). 
 The enlargement of adipocytes can greatly increase overall stress on the body, 
which can spark production of reactive oxygen species, free fatty acids, and other 
inflammatory factors (Gustafson and Smith, 2015). One inflammatory marker, called 
TNFα, is able to act synergistically with adipocytes and significantly bolster local 
inflammation (Gustafson and Smith, 2015).This creates a vicious cycle, with furthering 
inflammation and recruitment of other inflammatory cells (Gustafson and Smith, 2015). 
One study found that macrophages were distributed around necrotic adipocytes in a 
crown-like fashion, and that adipocyte death is what mediates macrophage recruitment 
(Budak et al., 2014). It has been found that among major causes, hypoxia is a major cause 
of adipocyte death (Gustafson and Smith, 2015).Once adipocytes reach the limit of 
diffusional oxygen transport (usually due to extensive hypertrophy), it is not able to get 
  24 
what it needs to fully survive (Gustafson and Smith, 2015).Visceral adipose tissue is also 
not able to expand its capillary network to make up for the increased surface area, often 
resulting in cell death (Gustafson and Smith, 2015). 
Origin of Visceral Adipose Tissue 
 In the embryo, fat tissue storage originates in the mesoderm (Gustafson and 
Smith, 2015). The embryonic mesoderm contains mesenchymal stem cells that are able to 
differentiate into precursors of adipocytes, chondrocytes, or osteoblasts (Gustafson and 
Smith, 2015). These mesenchymal stem cells allow continued renewal of precursor cells, 
and they are able to differentiate depending on presence of proteins called bone 
morphogenetic proteins (Gustafson and Smith, 2015). BMP4 cells encourage white 
adipogenesis, while BMP7 cells encourage brown adipogenesis (Gustafson and Smith, 
2015). White adipocytes function as lipid storage and can hold up to 1.0mcg of lipids in 
each cell (Gustafson and Smith, 2015). When a cell reaches its’ maximum storage, more 
white adipose cells are created or are accumulated as visceral fat deposits (Gustafson and 
Smith, 2015). Brown adipocytes are not harmful, but instead function to maintain body 
temperature and facilitate energy expenditure (Gustafson and Smith, 2015).  
Methods of Measurement 
There have been multiple methods of measurement used to assess levels of 
visceral fat, including bioelectrical impedance analysis (BIA), ultrasound, computed 
tomography (CT) scans, and dual X-ray absorptiometry (DXA) (Lee & Gallagher, 2008). 
However, not all methods produce equally accurate and reproducible forms of 
measurement. Bioelectrical impedance analysis (BIA) is commonly used to estimate 
body composition by measuring resistance (impedance) of a small electrical current 
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passed throughout the body to estimate total body weight, fat mass, and fat free mass 
(Lee and Gallagher, 2008). Although it is not indicated for use in individuals with 
pacemakers, BIA is easy to use for most individuals, portable, and is relatively affordable 
(Lee and Gallagher, 2008). However, it has been found that BIA is not accurate in 
individuals who are elderly due to reduction in total body water content; and many 
studies have found that values of fat free mass were overestimated in obese individuals, 
while the values were underestimated in normal-weight individuals, leading to potentially 
inaccurate results (Lee and Gallagher, 2008).  Computed tomography (CT) scans have 
also been widely used to quantify visceral fat due to its ability to generate exceptionally 
detailed images (Schmidt, 2012). A CT scan creates images by sending a quickly-rotating 
array of x-ray beams to create “slices” of cross-sectional images (Schmidt, 2012).  
However, CT scanning emits an undesirable amount of ionizing radiation, a known 
carcinogen, so it is no longer commonly used to estimate body fat (Schmidt, 2012). The 
gold standard of visceral fat measurement is now dual x-ray absorptiometry (DXA), 
which is noninvasive, appropriate for almost all age groups, and emits a relatively 
minimal amount of radiation (about 5% of a typical chest radiograph) (Lee and 
Gallagher, 2008). DXA has frequently been found to have good reproducibility and 
produce accurate images (Lee & Gallagher, 2008). DXA works by generating a flux of 
photons in combination with an x-ray generator that emits two beams consisting of 
different energy levels (Silver et al., 2010). Each beam quantifies a different tissue type; 
one energy level is absorbed by dense tissue such as bone (hence its frequent use for bone 
density scans), while the other energy level is absorbed by softer tissue, such as fat 
(Silver et al., 2010). This allows for total estimation of fat mass and fat-free mass based 
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on tissue density (Silver et al., 2010). However, a limitation of DXA scans is the 
scanning bed where the individual lays during the test has a weight limit, making it 
unsuitable for those who are above the limit (Silver et al., 2010). It is also not indicated 
for use in pregnant women due to risk of fetal harm from the radiation (Silver et al., 
2010). Despite these limitations, DXA is a very safe, noninvasive technique and 
continues to be the gold standard for visceral fat measurement in both healthcare and 
research. 
Waist Circumference 
Waist circumference is an easily-obtained measurement that can be used as a 
screening tool to identify if an individual is at an increased risk for developing metabolic 
disease. Specifically, excess abdominal fat can predict the risk of diseases such as 
hypertension, cardiovascular disease, type 2 diabetes, and dyslipidemia (Ruma et al., 
2012). Amount of abdominal fat, whether subcutaneous or visceral, is positively 
correlated with waist circumference (Ruma et al., 2012). According to 2015 Centers for 
Disease Control (CDC) guidelines, a man is at risk for aforementioned conditions if his 
waist circumference is greater than 40 inches, and a nonpregnant woman is at risk for the 
same conditions if her waist circumference is greater than 35 inches (Feller et al., 2010). 
Waist circumference is measured by placing a tape measure evenly around the middle of 
the body (without thick clothing, such as a sweater), just above the hip bones/iliac crest 
after the patient has exhaled, regardless of the location of the umbilicus (Feller et al., 
2010). A study by Berber and colleagues assessed a total of 8365 adults used waist 
circumference as a predictor of type 2 diabetes (T2DM) development (Berber et al., 
2001). Likelihood ratios of having T2DM were calculated based off of body mass index 
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(BMI) and waist circumference (Berber et al., 2001). The study found that the waist cut-
offs that were most accurate in determining risk were actually 35.4 inches for men and 
33.4 inches in women, which were below the CDC recommendations (Berber et al., 
2001). However, the study still illustrated the important and predictive relationship 
between a large waist circumference and assessing disease risk. 
 Benefits of Visceral Fat Reduction 
 There are multiple benefits associated with reducing visceral fat. Reduction in 
total body fat, weight, triglycerides, C-reactive protein, and blood glucose levels are some 
of the established benefits. A recent study involving a sample of overweight and obese 
adults with type 2 diabetes found that visceral fat reduction in response to a healthful diet 
and exercise resulted in an increase in levels of HDL (high density lipoprotein) 
cholesterol (Sanguankeo, et al., 2016). Visceral fat reduction is also associated with lower 
levels of retinol binding protein-4 (RBP4), an adipocytokine related to obesity and insulin 
resistance (Lee et al., 2008). Nondiabetic participants who followed a diet and exercise 
weight reduction program for 16 weeks had an average of 10.9% loss in total body 
weight, a 29% reduction in total visceral fat, and a 25.5% decrease in circulating retinol-
binding protein 4, or RBP4, levels (Lee et al., 2008). Nonalcoholic fatty liver disease 
(NAFLD) has also been associated with high levels of visceral fat (Finelli and Tarantino, 
2012). NAFLD is characterized by hepatocellular adiposity and inflammation, which can 
progress to cirrhosis, liver cancer, or even liver failure (Paschos and Paletas, 2009). The 
prevalence is approximately 75% in obese individuals (Paschos and Paletas, 2009). 
Insulin resistance and hyperglycemia, both thought to be due to biologically active 
visceral fat, can aid in the progression of NAFLD (Paschos and Paletas, 2009). A recent 
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study examined 30 subjects with biopsy-proven NAFLD with normal glucose tolerance 
(Marchesini et al., 2001). Nine subjects had “standard” NAFLD and 21 had 
steatohepatitis, a form of NAFLD characterized by hepatocyte damage and inflammation 
in addition to fatty deposits; all had high triglyceride and uric acid levels, and central 
obesity (Marchesini et al., 2001). A euglycemic glucose clamp found that glucose 
disposal was reduced in patients with NAFLD, similar to that of type 2 diabetics 
(Marchesini et al., 2001). They also found that NAFLD patients had a higher amount of 
free fatty acids and decreased postabsorptive hepatic glucose production (p=0.002) 
(Marchesini et al., 2001). Many of the NAFLD participants were also found to have 
evidence of iron overload, but their insulin sensitivity did not correlate with that status 
(Marchesini et al., 2001). The data was compared to data from type 2 diabetics, and it 
was found that even with normal glucose tolerance, the analyzed values were similar to 
the diabetic values (Marchesini et al., 2001). Dietary modifications and exercise are the 
two best methods for reducing and even reversing NAFLD and its associated 
complications (Paschos and Paletas, 2009). It has been established that the Mediterranean 
diet is preferred when treating NAFLD; a study involving 180 patients with metabolic 
syndrome and suspected NAFLD followed the diet for two years and resulted in reduced 
body weight, lower levels of CRP, interleukin-6, and improved insulin sensitivity 
(Espocito et al., 2004).  
Another benefit of visceral fat reduction is improved glucose tolerance. A recent 
rat model study found that removal of visceral fat resulted in improvement in insulin 
sensitivity and reduction in glycemic response (Foster et al., 2011). A study involving 
premenopausal women also found that visceral fat reduction resulted in improved plasma 
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glucose (Fujikowa et al., 1991). Forty premenopausal patients who presented with 
abdominal obesity were placed on a low calorie diet in effort to reduce visceral fat 
(Fujikowa et al., 1991). A CT scan was performed before and after starting the diet to 
assess total levels of visceral fat. The study found that a low calorie diet resulted in a 
greater loss in visceral fat and a minor loss in abdominal subcutaneous fat (Fujikowa et 
al., 1991). Improvements in plasma glucose levels, triglycerides, and total cholesterol 
were also observed (Fujikowa et al., 1991). 
Clinical Implications of Visceral Fat 
 Metabolic Syndrome 
Metabolic syndrome is a term used to describe a variety of metabolic conditions 
that increase risk of cardiovascular disease, type 2 diabetes, and overall mortality 
(Masquio et al., 2015). Conditions that characterize metabolic syndrome include insulin 
resistance, hypertension, obesity, dyslipidemia, and a large waist circumference that 
aligns with CDC guidelines (Masquio et al., 2015). A recent study involving 195 obese 
adults were recruited and had their insulin, glucose, liver enzymes, and leptin levels 
analyzed (Masquio et al., 2015). They were weighed via a BODPOD and had their 
visceral and subcutaneous fat imaged via ultrasound (Masquio et al., 2015). Analysis of 
values discovered that waist circumference was positively correlated with visceral fat and 
the number of metabolic syndrome symptoms present (Masquio et al., 2015). Those with 
established metabolic syndrome also had hyperglycemia, a higher body mass, BMI, total 
cholesterol, liver enzymes, and lower adiponectin (Masquio et al., 2015). Although 
visceral fat levels were assessed via ultrasound, this study still identified the important 
link between amount of visceral fat and manifestation of metabolic syndrome.  
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Obesity 
 According to 2016 CDC guidelines, obesity is defined by having a body mass 
index (BMI; kg/m2) of 30 or higher and an excessive amount of adipose tissue (“Defining 
Adult Overweight and Obesity”, 2016). Visceral fat is a type of adipose tissue that is 
found packed between organs in the abdominal cavity, or in the intraperitoneal area 
(Klein, 2004).  It is thought that visceral fat is created as a result from free fatty acid 
(FFA) release by the portal vein (Klein, 2004). A direct relationship between hepatic free 
fatty acid metabolism and visceral fat deposits has been established, but the rate of 
hepatic FFA release differs for each individual (Klein, 2004). A recent study explored the 
association between lifestyles, body fat, and demographics. Over 3300 participants were 
enrolled in this study and completed a food frequency questionnaire and had their 
anthropometric measurements taken (Ramos de Marins, 2001). They found that of the 
44.9% of participants classified as overweight or higher, 39.2% of them had a significant 
amount of visceral fat (Ramos de Marins, 2001). The group that was found to have the 
highest prevalence of obesity and related health problems were middle aged females 
(Ramos de Marins, 2001). Obesity, especially central obesity, is a prevalent health 
concern and is related to a variety of comorbidities  
 Inflammation 
 Noninfectious, chronic inflammation is a major consequence of having a 
substantial amount of visceral fat (Fontana, et al., 2007). The main cause of inflammation 
related to visceral fat is thought to be caused by stress reactions caused by frequent 
metabolic overload (Monteiro and Azevedo, 2010). It has been found that during times of 
high fat intake, adipose tissue is unable to utilize incoming fat, causing it to deposit into 
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surrounding organs, most likely the liver (Monteiro and Azevedo, 2010). This contributes 
to insulin resistance as well as the progression of an inflammatory state (Monteiro and 
Azevedo, 2010). High fat intakes have also been correlated with low intake of 
antioxidant-containing foods, which further contributes to a state of inflammation 
(Monteiro and Azevedo, 2010). The mechanism behind chronic inflammation begins with 
the immune system. During a “typical” inflammatory response, inflammatory mediators 
such as cytokines and eicosanoids are released and sent to the site of insult (Monteiro and 
Azevedo, 2010). This triggers a release of white blood cells that release chemicals in 
efforts to defeat the offending unknown (Monteiro and Azevedo, 2010). The typical 
response resolves by apoptosis of inflammatory cells, but in the case of visceral fat, 
apoptosis does not occur (Monteiro and Azevedo, 2010). This prolongs the state of 
inflammation and is what characterizes the chronic, low-grade inflammatory state of 
obesity. Many researchers have called obesity-associated inflammation 
“metaflammation”, aka metabolically triggered inflammation (Monteiro and Azevedo, 
2010). Visceral adipocytes have been found to synthesize various proinflammatory 
substances, such as tumor-necrosis factor alpha, chemokines, and various cytokines, 
illustrating how visceral fat can mediate the inflammatory response (Monteiro and 
Azevedo, 2010).    
Insulin Resistance 
The relationship between excess abdominal fat and insulin resistance was first 
recognized by Dr. Jean Vague in 1947 (Klein, 2004). Many people who have a high 
amount of visceral fat also have insulin resistance that is likely to progress into type 2 
diabetes. A recent study tested if type 2 diabetes risk and concurrent insulin resistance 
  32 
were decreased following visceral fat reduction and overall body size (Fujimoto et al., 
2007). Over 1100 subjects were recruited, all of which had impaired insulin action and a 
significant presence of abdominal fat (Fujimoto et al., 2007). They were instructed to 
follow a lifestyle change regimen involving a reduced calorie diet and exercise for one 
year (Fujimoto et al., 2007). A computed tomography (CT) scan was completed at the 
start and end of the study as well as blood glucose and insulin level assessment (Fujimoto 
et al., 2007). After one year of completion, a CT scan found that visceral fat was reduced 
by 18% for women and 24% for men (Fujimoto et al., 2007). A decrease in fasting blood 
glucose levels and an increase in insulin sensitivity were also observed, decreasing 
overall diabetes risk (Fujimoto et al., 2007). 
Another study examined if presence of visceral fat was strongly correlated with 
development of insulin resistance and type 2 diabetes (Preis et al., 2010). Participants 
underwent a CT scan to determine levels of visceral fat and insulin resistance was 
measured via radioimmunoassay (Preis et al., 2010). Data was adjusted for age, gender, 
alcohol or tobacco use, and menopausal status (Preis et al., 2010). It was found that the 
odds ratio for insulin resistance per standard deviation of visceral fat levels was 3.5, 
showing that there is a strong correlation between insulin resistance and visceral 
adiposity (Preis et al., 2010).
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                                                             CHAPTER 3 
METHODS 
Participants and Study Design 
 Participants 
Participants were recruited after Arizona State University Institutional Review Board 
(IRB) approval was obtained (Appendix C). It was desired that at least 30 participants 
would be recruited for this study (Appendix B). Participants were recruited starting 
December 2016 via flyers, emails, and word of mouth from the Arizona State University 
Downtown Phoenix Campus and surrounding community. Individuals who were 
interested in the study filled out a SurveyMonkey questionnaire 
(www.surveymonkey.com) to determine eligibility. Participants were between the age of 
18-45, free from any untreated medical condition(s), and not taking insulin or other 
medications that can affect body weight. Women had a waist circumference greater than 
or equal to 33 inches and men had a waist circumference greater than or equal to 38 
inches. Women were excluded if they were pregnant or were planning a pregnancy within 
the next 3 months. Participants were also excluded if they recently had abdominal 
surgery; if they had a condition that can cause abdominal distention or swelling, such as 
ascites, pancreatitis, diverticulitis, diverticulosis, Crohn’s disease and/or irritable bowel 
syndrome; and if they were taking digoxin or diuretics. Subjects were willing to adhere to 
the study design (vinegar drink or pill consumption), travel to the Arizona Biomedical 
Collaborative on three separate occasions, or ABC, building (425 N. 5th Street, Phoenix, 
AZ, 85004) for two one-hour visits and one 30-minute visit, and fill out a diet record on 
two occasions. They also provided written consent to officially be included in the study, 
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which occurred during the initial 30-minute visit at the ABC building. Subjects were 
provided with more information about the study, such as the length of the trial, data 
collection methods, possible risks and benefits, and the contact information for the 
researchers. At least one researcher was present at each visit to provide further detail 
about the study and/or answer questions. 
 Study Design and Procedure 
This study was conducted as an 8-week, randomized, placebo-controlled, parallel 
arm, experimental trial. After the all of the initial consent meetings were completed, the 
subjects were stratified by gender, age, and weight, then randomized into two groups: the 
intervention group, vinegar drink (VIN) or the control group, vinegar pills (CON). The 
participants knew which treatment they are given but they did not know which group 
(control vs. placebo) they are in. Those who received the VIN were instructed to drink 2 
tablespoons of red wine vinegar (provided) mixed with at least 8oz water before a meal, 
twice per day for weeks 1-8 of the trial. Those in the CON group were instructed to take 
two vinegar pills (provided) before a meal each day for weeks 1-8 of the trial. 
Participants were instructed to maintain their current diet and exercise habits during the 
study. They were given two diet record forms to fill out, one at baseline and again at 
week 8 to ensure typical intake hasn’t changed.  Fasting blood draws, a DXA scan, 
height, weight, and waist circumference measurements were taken before the intervention 
began and after it ended. Ten dollar gift cards were given to participants at week 8 of the 
study at the final visit upon completion of the trial. 
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Study Variables 
 The independent variable in this study was acetic acid ingestion. Those in the VIN 
group were instructed to consume a total of 4 tablespoons each day (providing 3.6 g 
acetic acid total), mixed with water. They received an 8-week supply of bottles of the red 
wine vinegar (Mantova Red Wine Vinegar, Mantova, Broccostella, Italy). Red wine 
vinegar was chosen because of its palatability compared to other vinegars and 
affordability. For some, a limitation could be the taste. However, consuming it mixed 
with water helps dull the sharp flavor. If they are in the CON group, they were provided 
with one bottle of vinegar pills (Apple Cider Vinegar Tablets, NowFoods, Bloomingdale, 
IL). They were instructed to swallow two whole pills each day (providing 0.0225 mg 
acetic acid total). The main dependent variable in this project was visceral fat mass. It 
was expected that those who are in the VIN group would experience a greater loss of 
visceral fat in comparison to those in the CON group.   
Protocol Procedures  
 The first visit was approximately 30 minutes long. After participants provided 
consent, they had their height, weight, and waist circumference measured. If the 
measurements met the requirements of the study, the participant were considered eligible 
for the study and were allowed to proceed with the trial. They also completed a medical 
history questionnaire (Appendix G) and a 24-hour diet recall (Appendix F). The medical 
history questionnaire ensured the participants did not have any known medical conditions 
or took any medication that would deny them participation in the study.  The recall had 
them list their total food and beverage consumption for the past 24 hours, specifying what 
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they ate, how much, and how it was prepared to the best of their knowledge. Their second 
and third visits were also scheduled at this visit. 
 The second visit was approximately an hour long. Subjects again had their height, 
weight, and waist circumference measured. They will have had to fast for at least 8 hours 
prior to this visit, with the exception of plain water. They had a blood draw performed by 
a certified phlebotomist to test their fasting blood glucose and insulin levels. The 
participants then had a DXA scan performed by a certified radiologic technician. All 
women participating in this study needed to have a urine pregnancy test done before 
having the DXA scan. After the scan, they were given an 8-weeks supply of either the red 
wine vinegar or vinegar pills depending on which group they were randomized into. 
Instructions regarding proper consumption were given; subjects were told to adhere to the 
same treatment for the entire 8 weeks. A compliance calendar was also given for the 
participants to mark off each day they take their supplement. 
Each week of the trial, all participants were emailed to provide reminders and 
give them an opportunity to ask questions if needed. 
Fasting blood draws, DXA scans, pregnancy tests, a 24-hour diet recall, and 
anthropometric measurements were repeated after the 8 weeks passed. Participants turned 
in their compliance calendar to track adherence to study protocol. They also completed an 
exit survey to obtain their thoughts on the trial and explain any symptoms or problems 
they may have experienced during the intervention (Appendix H).  Participants were 
compensated with a $10 gift card to Subway upon completion of the trial. 
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Laboratory Analyses 
Participants arrived at the test center after fasting for 8 hours and had their bloodwork 
via venipuncture performed by a certified phlebotomist or nurse. Approximately 10mL of 
blood was drawn (2 mL via gray top vacutainer tube, 8.5mL via red top serum vacutainer 
tube). Standard Blood Specimen Collection by Venipuncture for Study Protocols and 
Procedures was used (Arizona State University, 2010). Insulin levels were assessed using 
a radioimmunoassay (RIA) kit (Human Insulin-Specific Fasting blood glucose levels 
were measured via a Cobas analyzer (Cobas c111 Analyzer, Cobas, Indianapolis, IN). 
Participant’s HOMA-IR score was estimated using the standard HOMA calculation: 
fasting glucose (mg/dL)*fasting insulin (uU/mL)/405. Females participating in the study 
also provided a urine sample (at least 2 fluid ounces) to confirm that she was not pregnant 
(Medline Urinalysis Reagent Strips, Medline, Mundelein, IL).  Each participant then had 
a dual x-ray absorptiometry, or DXA (Lunar iDXA, General Electric, Fairfield, CT), scan 
performed by a certified radiologic technician to assess their current level of body fat, 
including visceral fat mass. DXA scanning has been validated as the gold standard for 
body fat assessment due to its accuracy and noninvasive protocol. Limitations of DXA 
scanning include exposure to a very small amount of radiation, but the technician ensures 
that all preventative measures are taken to use the lowest dose possible to obtain an 
accurate scan. Pregnant women should not have a DXA scan due to the risk of fetal harm 
from the radiation, which is why a pregnancy test will be done on each female participant 
to ensure that she is not pregnant before testing.   
 
 
  38 
Statistical Analyses 
Data are reported as mean values + standard deviation. The Statistical Package for 
Social Sciences (SPSS) software (SPSS Incorporated, Chicago, IL, USA) version 24 was 
used to complete the statistical analyses of the data. A p-value of <.05 was considered 
significant. Shapiro-Wilk, Kolmogorov-Smirnov, and independent t-tests were conducted 
to test normality of the data and compare means of the control vs. placebo group. 
Repeated measures ANOVA (analysis of variance) was conducted for statistical analyses. 
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CHAPTER 4 
RESULTS 
Recruitment for this trial began in December 2016 at Arizona State University’s 
Downtown Phoenix campus and ended in March 2017. An online recruitment screening 
survey (www.surveymonkey.com) was advertised via Listservs, flyers throughout 
campus and the downtown area, and social media postings on ASU-affiliated Facebook 
pages. The survey was open from December 16, 2016 until March 22, 2017. A total of 
165 respondents completed the survey, 36 were excluded based on their responses, and 
129 were emailed to set up their first visit that involved confirming and validating their 
responses and obtaining written consent. Forty nine came to the first visit, and 19 were 
then excluded because they did not meet the criteria. Sixteen were excluded because they 
did not meet the required waist circumference measurement; one due to dietary 
restrictions, one due to transportation and scheduling issues, and one was already taking 
vinegar supplements. Thirty participants were deemed eligible to start the 8-week trial. 
These subjects were then stratified by age, gender, and BMI, then assigned a group based 
on a coin flip: the experimental (VIN) group (n=15) or control (CON) group (n=15). Of 
the 30 subjects who started the trial and data collection, 23 finished the trial. Eleven 
participants finished in the vinegar group with an average of 98.3% reported compliance, 
and 12 in the control group with an average of 87.8% reported compliance. Subject 
adherence to the supplements was tracked via a compliance calendar. Four participants 
dropped due to attrition, one due to pregnancy, one due to health problems unrelated to 
the trial, and one due to an adverse reaction to the vinegar. In total, one man and 22 
women completed the trial. 
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The variables used to determine participant eligibility were age, height, weight, 
BMI, and waist circumference. These values were measured using standard protocol 
during the first screening visit of the study. Analysis via independent samples t-tests 
revealed no significant differences between VIN and CON groups at baseline, with the 
exception of height (p=0.024) (Table 2). Participants for this study were between ages 
18-45. For the VIN group, participants had a mean age of 28.5+6.9 years, and the CON 
group had a mean age of 28.0+7.7 years. Participants were between 150-185cm tall, with 
the VIN group having an average height of 160.6+4.3 cm, and the CON group having an 
average height of 166.7+2.08 cm. Weight between both groups was between 53.9-131.2 
kg (118.5-288.2lbs), with the VIN group having a mean weight of 75.8+13.1 kg, and the 
CON group having a mean weight of 78.9+20.2 kg at baseline. Participant BMI values 
ranged from 22.5-45.5 kg/m2. At baseline, waist circumference for the participants 
ranged between 33-50 in. As a whole, the participants averaged 93.3% compliance for the 
trial. Compliance was tracked via a compliance calendar and was given to each 
participant at the beginning of the trial. The VIN group averaged 98.4+1.9% compliance 
(n=9), while the CON group averaged 87.8+26.5% compliance (n=9). A total of 5 
participants lost their compliance calendar; participant compliance ranged from 19.6-
100%. 
Table 2: Baseline Characteristics by Group1 
 VIN (n=11) CON (n=12) p-value 
Age (years) 28.5+6.9 28.0+7.7 0.861 
Height (cm) 160.6+4.3 166.7+2.08 0.024 
Weight (kg) 75.8+13.1 78.9+20.2 0.676 
BMI (kg/m2) 29.3+4.3 28.2+5.8 0.603 
Waist circumference 
(in) 
36.9+4.06 36.0+4.8 0.693 
% Compliance   98.4+1.9 (n=9) 87.8+26.5 (n=9) 0.270 
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1Data reported as mean + standard deviation; p represents independent samples t-test. 
Data considered significant at p<0.05. 
 
Anthropometric measurements and a DXA scan were obtained before and after 
the intervention. Anthropometrics were measured using standard protocol. The DXA scan 
allowed the visceral and total body fat of the participants to be quantified. One participant 
was removed as an outlier for the visceral fat measurement, as they were 3 standard 
deviations away from the mean. Using the repeated measures ANOVA analysis, there 
were no statistically significant changes in anthropometric measurements between weeks 
1 and 8 of the study. However, the VIN group experienced a 2% decrease in visceral fat 
(cm3), and although it was not statistically significant (Table 3) (Figure 1A). 
Table 3: Changes in Anthropometrics Between Week 1 and Week 82 
  VIN (n=11) CON (n=12) p-value Effect 
Size 
Weight (kg)      
 Pre 75.6+13.4 79.0+20.3 0.983 0.000 
 Post 75.8+12.6 79.3+20.4 
BMI (kg/m2)      
 Pre 29.6+4.4 28.2+5.8 0.772 0.004 
 Post 29.8+4.0 28.2+6.0 
Waist 
circumference (in) 
     
 Pre 36.4+3.4 36.0+4.7 0.222 0.070 
 Post 36.0+4.3 34.9+4.7 
% body fat (BIA)      
 Pre 37.1+7.4 35.1+8.2 0.712 0.007 
 Post 37.0+6.4 34.7+8.5 
Visceral fat (cm3)       
 Pre 721.7+567.9 507.4+579.9 
(n=11) 
0.256 0.064 
 Post 703.1+547.6 516.2+590.4 
(n=11) 
Total fat (kg)      
 Pre 35.7+17.5 28.6+14.5 0.257 0.061 
 Post 31.9+99.3 28.5+14.7 
2Data reported as mean + standard deviation; p represents repeated measures ANOVA. 
Data considered significant at p<0.05. Effect sizes >0.140 are considered large. 
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Figure 1.  A: Comparison of visceral fat (cm3) between groups at week 1 and week 8 
(p=0.256). Data considered significant at p<0.05. Data represents VIN: n=11. CON: 
n=11. Visceral fat quantified via DXA.  B: Comparison of waist circumference (in) 
between groups at week 1 and week 8 (p=0.222). Data considered significant at p<0.05. 
Data represents all participants who completed the trial (n=23). VIN: n=11. CON: n=12 
 
 
 
 
Figure 2: Comparison of total body fat (kg) between groups at week 1 and week 8 
(p=0.257). Data considered significant at p<0.05. Data represents all participants who 
completed the trial (n=23). Total body fat quantified by DXA. VIN: n=11. CON: n=12 
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Figure 3: Comparison of individual changes in visceral fat at week 8. Data 
represents VIN: n=10. CON: n=12. 
 
Fasting blood draws were obtained by a certified phlebotomist from each 
participant pre- and post-trial. Participants had to fast for 8 hours prior to their scheduled 
blood draw. Verbal affirmation ensured patients had fasted for the required time. One 
participant was not able to have a full draw due to difficulties obtaining the sample, 
which explains the smaller sample size for the insulin data for the CON group.  The VIN 
group experienced a slight decrease in insulin, but the change was not statistically 
significant (p=0.125) (Figure 3). The change in HOMA-IR is a statistical trend (p=0.079) 
with a large effect size (Figure 4). Other values did not exhibit any statistically significant 
changes over the course of the trial (Table 4). 
 Table 4: Changes in Blood Indices Between Week 1 and Week 83  
  VIN (n=11) CON (n=12) p-value Effect Size 
Insulin (uU/mL)      
 Pre 17.1+10.0 14.0+.4 (n=11) 0.125 0.114 
 Post  14.9+9.0 14.9+8.3 (n=11) 
V
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Glucose (mg/dL)      
 Pre 94.0+6.2 93.0+7.3 0.643 0.012 
 Post 93.9+4.8 94.6+6.7 
HOMA-IR (units)      
 Pre 4.3+2.6 3.2+1.6 0.079 0.153 
 Post 3.6+2.2 3.5+2.1 
3Data reported as mean+ standard deviation; p represents repeated measures ANOVA. 
Data considered significant at p<0.05. Effect sizes >0.140 are considered large. 
  
 
 
 
             
Figure 4: Comparison of fasting insulin (uU/mL) between groups at week 1 and week 8 
(p=0.125). Data considered significant at p<0.05. Data represents VIN: n=11. CON: 
n=11. 
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Figure 5: Comparison of HOMA-IR (score) between groups at week 1 and week 8 
(p=0.079). Data considered significant at p<0.05. Data represents all participants who 
completed the trial (n=23). Visceral fat quantified via DXA. VIN: n=11. CON: n=12. 
HOMA-IR: Homeostatic Model Assessment of Insulin Resistance. 
 
Participants completed a 24 hour dietary recall before and after the trial during 
their meetings with the research team. The VIN group consumed an average of 1586+686 
calories before the trial, and an average of 1639+728 calories after the trial. The CON 
group consumed an average of 1958+1019 calories before the trial, and 2086+1327 
calories after. However, there is not a significant change in the groups (p=0.889). It is 
interesting to note that the average protein intake increased and the average carbohydrate 
intake decreased in the VIN group between weeks 1 and 8. The other macronutrient 
values did not any show any statistically significant changes over the course of the trial 
(Table 5). 
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Table 5: Dietary Data4 
  VIN (n=11) CON (n=12) p-value 
Calories     
 Pre 1586+686 1958+1019 0.889 
 Post  1639+728 2086+1327 
Carbohydrate 
(g) 
    
 Pre 208+103 185+104 0.292 
 Post 193+100 249+164 
Protein (g)     
 Pre 53+24 107+100 0.352 
 Post 58+35 87+59 
Total fat (g)     
 Pre 61+31 78+51 0.971 
 Post 66+41 82+62 
Total fiber 
(g) 
    
 Pre 17+8 23+12 0.320 
 Post 19+16 19+11 
 4Data reported as mean + standard deviation; p represents independent samples t-test. 
Data considered significant at p<0.05. 
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CHAPTER 5 
DISCUSSION 
          Studies in animal models have shown that vinegar supplementation is effective in 
reducing visceral fat. This 8-week, randomized, placebo-controlled, parallel arm, 
experimental trial looked to examine if this relationship exists in humans. Twenty three 
participants completed this study, which failed to show any significant decreases in 
visceral fat in the VIN vs. CON groups (p=0.256), but showed a promising trend in 
HOMA-IR scores for the VIN vs CON groups (p=0.079). It is likely that due to a smaller 
sample size, there was not sufficient power to detect a significant change in study 
parameters. Although there were thirty participants originally recruited, a total of 7 
participants dropped the study, thus weakening the total power of this study. A reverse 
power calculation found that there was only 21% power to detect a treatment difference 
between the groups (with n=23), using a 0.05 significance level. It is also possible that 
participants did not comply with intervention protocols (missing a dose, not fasting 
before testing), despite the best efforts of the researchers. An exit survey was completed 
by all participants who finished the trial to gauge what the participants experienced 
throughout the intervention (Appendix G). Many participants in the VIN group reported 
that they were nauseous after taking the vinegar. They also reported stomach burning and 
reflux if the vinegar was consumed too late at night. One participant also noted that 
towards the end of the 8 weeks, their front teeth felt eroded and their sweat smelled like 
vinegar. It is interesting to note that there are vinegar pills on the market that have a 
higher acetic acid content than the pills used in this study; this may be a more agreeable 
method of vinegar ingestion for future studies. Participants in the CON group reported 
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very few negative side effects; one participant said that the supplement irritated their 
stomach if it was taken too early or late, another participant said that their eyes felt tired 
each time after consuming their supplement. A compliance calendar was given to each 
participant to track their participation that ranged from 19.6-100%. The VIN group 
averaged 98.4+1.9% compliance (n=9), while the CON group averaged 87.8+26.5% 
compliance (n=9). Five participants lost their calendar and were not entirely sure of the 
number of days that they missed. 
           The study length could also be a limiting factor, as 8 weeks could be considered a 
relatively short time frame to produce a significant change in visceral fat. A study 
involving 27 middle aged women used a 16 week exercise intervention to assess changes 
in visceral fat; although they found that the visceral fat decreased, it also was not 
considered statistically significant (Irving et al., 2009). Another study involving 32 
overweight men and women examined the potential of rosehip extract supplementation to 
reduce visceral fat over a 12 week period (Nagatomo et al., 2015). This study was slightly 
longer than ours, but still failed to exhibit statistical significance even though there was a 
change in visceral fat between the groups (p=0.21) (Nagatomo et al., 2015). However, a 
study by Yip and colleagues found that in a group of 18 obese adults, following a calorie 
deficit diet and supplementing sibutramine (appetite suppressant) daily for 6 months 
resulted in an overall 31% reduction in visceral fat, which was statistically significant 
(p=0.0003) (Yip et al., 2001). Previous animal studies have been in situ and therefore do 
not have an applicable timeframe of acetic acid consumption that would be appropriate to 
compare this study to. However, the study by Kondo et al. found that after 12 weeks of 
consuming vinegar beverage, 175 overweight participants showed a statistically 
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significant reduction in total body fat area (-14cm2 in comparison to baseline 
measurements), citing AMPK as the main mechanism behind the loss (p=0.085) (Kondo 
et al., 2009). However, the protocol of Kondo’s study was slightly different than the 
present study; participants were not allowed to consume alcohol or perform exercise 
before testing days, they had to fast 12 hours before testing, and no “functional foods” 
were to be consumed during the 12 week intervention. Our change in visceral fat (cm3) 
for our VIN group was a 2% decrease, and Kondo’s change in total visceral fat area 
(measured by CT scan) for their high-dose vinegar group (1.5g acetic acid) averaged a 
2.8% decrease (Kondo et al., 2009).  
            In conclusion, our study did not support our hypothesis. The hypothesis that daily 
red wine vinegar consumption will reduce visceral fat in adults with central obesity was 
not supported by our data. Further research is indicated, particularly with a larger sample 
size, in order to fully determine if vinegar consumption is effective in reducing visceral 
fat in healthy adults with larger waist circumferences.   
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I am a graduate student in the School of Nutrition and Health Promotion at Arizona State 
University and am conducting a research study to examine health benefits of vinegar 
supplementation.  I am inviting your participation in the screening process, which will 
consist of answering questions regarding health history, demographics, and scheduling 
availability. You have the right to not answer any question, and to stop participation at 
any time. 
We are recruiting health adults who have a little extra belly fat. Your participation in this 
survey and study is voluntary. If you choose not to participate or to withdraw from the 
study at any time, there will be no penalty.  Your responses to this survey will be 
confidential.  If you meet the criteria for this study, you will be contacted to schedule an 
in-person appointment at the downtown campus of Arizona State University. 
 
If you have any questions concerning the research study, please contact the research team 
at obaker2@asu.edu. If you have any questions about your rights as a subject/participant 
in this research, or if you feel you have been placed at risk, you can contact the Chair of 
the Human Subjects Institutional Review Board, through the ASU Office of Research 
Integrity and Assurance, at (480) 965-6788. 
 
By selecting “I agree” below you are agreeing to continue forward with the survey and be 
contacted by investigators (via e-mail) to schedule an appointment, should you qualify. 
1. What is your email? w 
 
2. Are you an ASU student, staff, or faculty on the downtown campus? w 
Yes 
No 
3. How old are you? 
w 
Age (years)  
4. Are you male or female? w 
Male 
Female 
5. Do you smoke cigarettes? w 
Yes 
No 
6. Do you consider yourself to have extra belly fat? w 
Yes 
  66 
No 
Unsure 
7. How tall are you? w 
Height (inches) (Note: 5 feet=60 inches)  
8. How much do you weigh? w 
Weight (pounds)  
9. Are you generally healthy? (e.g., not seeing a doctor for a medical condition) w 
Yes 
No 
10. Do you take a prescription drug daily? (excluding birth control) w 
Yes 
No 
11. Are you willing to drink a diluted vinegar drink daily or consume a vinegar pill 
daily for 8 weeks? w 
Yes 
No 
12. Do you have any food allergies or diet restrictions? w 
Yes 
No 
13. Have you lost or gained more than 10 pounds in the last six months? w 
Yes 
No 
Unsure 
14. If female, are you pregnant, or hope to get pregnant, in the next few months? w 
Yes 
No 
15. Are you ok with providing a small blood sample on two occasions during the 
research trial? w 
Yes 
No 
16. Are you willing to meet with investigators at the ABC1 building on the ASU 
Downtown campus on 3 occasions? w 
Yes 
No 
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The Impact of Vinegar on Fat Metabolism and Blood Values 
INTRODUCTON 
The purposes of this form are (1) to provide you with information that may affect your decision  
as to whether or not to participate in this research study, and (2) to record your consent if  
you choose to be involved in this study. 
RESEARCHERS 
Dr. Carol Johnston, a Nutrition professor, and Olivia Baker, a graduate student, at Arizona  
State University Downtown, Phoenix, have requested your participation in a research study. 
STUDY PURPOSE 
The purpose of this 8-week long research study is to evaluate the impact of vinegar ingestion  
on fat metabolism and blood glucose concentrations.   
DESCRIPTION OF RESEARCH STUDY 
You have indicated to us that you are 18-45 years of age and healthy. If female, you are not currently 
pregnant or planning a pregnancy. Also, you have not had abdominal surgery or chronic conditions 
involving your digestive track. This study will involve the completion of a brief health history  
questionnaire to demonstrate the absence of other conditions that may contraindicate participation.  
 
This research entails that you visit our test facilities on three occasions on ASU’s Downtown Phoenix 
campus. At your first visit (lasting ~30 minutes) you will complete a health history questionnaire and          
a 24-h diet recall to confirm your eligibility. Your height, weight, and waist circumference will be 
measured.  You will be scheduled for the second visit which is the start of the 8-week study.  You will   
need to fast for this visit (no food or drink with the exception of water for >8 hours).  A blood sample       
will be taken from an arm vein (~2 tablespoons), and the DXA scan will take place.  For the DXA scan 
(performed using an FDA‐approved Dual‐energy X‐ray Absorptiometry machine) you will be asked to      
lie face up on an open, padded table for 7 minutes while the scanner arm of the DXA machine passes      
over the entire body. You can wear regular clothing but any metal (clothing or accessory) must be     
removed. You will be exposed to a small amount of radiation (1‐4 microSieverts) that is within an 
acceptable range per the FDA. For comparison, you would be exposed to approximately 80      
microSieverts on a transatlantic airline flight of 8 hours, 50 microSieverts living in Denver, Colorado,        
at an elevation of 5,000 feet for approximately 4 weeks, or 30 to 40 microSieverts during a typical chest      
x‐ray. (For test accuracy, you will be asked about test procedures using barium/isotopes in the recent       
past and be scheduled for your visit with an adequate lapse of time.)  At this visit you will also receive    
your vinegar supplement which is to be consumed daily as instructed.  This visit is expected to last   ~1 
hour.  The third visit will mirror visit 2, and you will receive a $10 gift card.   
RISKS 
Mild discomfort due to the venous blood draw may occur.  Blood sampling may be 
associated   with nausea, dizziness, faintness, and bruising at the site of needle insertion.   
A trained phlebotomist will collect the blood and manage participant reaction as  
appropriate.  Regarding the DXA scan, anytime you are exposed to radiation there  
is potential risk. Females will take a urine pregnancy test prior to the DXA scan to  
demonstrate the absence of a pregnancy. A certified X‐ray technician will complete all DXA  
scans.  
BENEFITS  
You may not benefit from this study, but once the study is complete you will be provided with  
your test results if desired including bone mineral density and body fat composition. 
NEW INFORMATION 
If the researchers find new information during the study that would reasonably change your decision 
 about participating, then they will provide this information to you. 
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       CONFIDENTIALITY 
 All information obtained in this study is strictly confidential unless disclosure is required by  
law. The results of this research study may be used in reports, presentations, and  
publications, but your name or identity will not be revealed.  In order to maintain confidentiality  
of your records, Dr. Johnston will use subject codes on all data collected, maintain a master 
 list separate and secure from all data collected, and limit access to all confidential information  
to the study investigators.   
WITHDRAWAL PRIVILEGE 
You may withdraw from the study at any time for any reason without penalty or prejudice  
toward you.  Your decision will not affect you any manner. 
COSTS AND PAYMENTS 
You will receive a $10 gift card at the completion of data collection. 
COMPENSATION FOR ILLNESS AND INJURY 
If you agree to participate in the study, then your consent does not waive any of your legal  
rights. However, in the event of harm, injury, or illness arising from this study, neither  
Arizona State University nor the researchers are able to give you any money,  
insurance coverage, free medical care, or any compensation for such injury.  Major injury is  
not likely but if necessary, a call to 911 will be placed.  
VOLUNTARY CONSENT 
Any questions you have concerning the research study or your participation in the study,  
before or after your consent, will be answered by Dr. Carol Johnston, 500 N. 3rd St.,  
Phoenix, AZ 85004. [602-827-2265]  
 
If you have questions about your rights as a subject/participant in this research, or if you feel  
you have been placed at risk, you can contact the Chair of the Human Subjects  
Institutional Review Board, through the ASU Research Compliance Office, at 480-965 6788.   
 
This form explains the nature, demands, benefits and any risk of the project.  By signing this form you 
agree knowingly to assume any risks involved.  Remember, your participation is voluntary.  You may 
choose not to participate or to withdraw your consent and discontinue participation at any time without 
penalty or loss of benefit.  In signing this consent form, you are not waiving any legal claims, rights, or 
remedies.  A copy of this consent form will be given to you.   
 
 
 
Your signature below indicates that you consent to participate in the above study.   
______________________________      ______________________________  ______ 
Subject's Signature             Printed Name         Date 
____________________________   ________________________________      
Contact phone number                     Email    
 
INVESTIGATOR’S STATEMENT 
"I certify that I have explained to the above individual the nature and purpose, the  
potential benefits, and possible risks associated with participation in this research  
study, have answered any questions that have been raised, and have  
witnessed the above signature. These elements of Informed Consent conform to the 
Assurance given by Arizona State University to the Office for Human Research Protections  
to protect the rights of human subjects. I have provided the subject/participant a copy of  
this signed consent document." 
 
 
Signature of Investigator____________________________________        Date___________ 
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HEALTH HISTORY QUESTIONNAIRE                                ID#___________________ 
1. Gender:  M    F 
 
2. Age:  __________ 
 
3. Have you lost or gained more than 10 lbs in the last 12 months?         Yes         No 
     If yes, how much lost or gained? _________     How long ago? ___________ 
 
4. Ethnicity: (please circle one)  Native American     African-American     Caucasian     Hispanic     
Asian     Other 
 
5. Education (please circle)   High school diploma     AA/vocational degree     College degree    MS 
degree     PhD degree 
 
6. Do you smoke?  No, never ________   
        Yes _______     # Cigarettes per day = ________                               
                               I used to, but I quit _______ months/years (circle) ago 
 
7. Women only:  Have you ever been pregnant? ___________________ 
                             If yes, date of last pregnancy? ___________ 
              Are you pregnant now or plan a pregnancy in the next 3 months?       Yes           
No 
 
8.  Do you take any medications regularly?     Yes No           If yes, list type and frequency: 
     
Medication    Dosage    Frequency 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________’ 
 
 
9. Do you currently take supplements (vitamins, minerals, herbs, etc.) ?    Yes    No         
If yes, list type and frequency:                               
     
Supplement    Dosage    Frequency 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________ 
 
10.  Please check (YES/NO) if you currently have or if you have ever been clinically 
diagnosed with any of the following  diseases or symptoms: 
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 YES NO  YES NO 
Coronary Heart Disease   Chest Pain   
High Blood Pressure   Shortness of Breath   
Heart Murmur   Heart Palpitations   
Rheumatic Fever   Any Heart Problems   
Irregular Heart Beat   Coughing of Blood   
Varicose Veins   Feeling Faint or Dizzy   
Stroke   Lung Disease   
Diabetes   Liver Disease   
Low Blood Sugar   Kidney Disease   
Bronchial Asthma   Thyroid Disease   
Hay Fever   Anemia   
Leg or Ankle Swelling   Hormone Imbalances   
Eating Disorder   Depression   
              
 
 
 
11.  Have you ever had abdominal surgery?    Yes      No 
 
12.  Do you have any of the conditions listed below?      Yes         No                                    
             acid reflux, ascites, pancreatitis, diverticulitis/diverticulosis, Crohn’s disease, 
and/or irritable bowel syndrome 
13.  Please circle the number of times you did the following kinds of exercises for more 
than 15 minutes last week. 
Mild exercise (minimal effort):   
Easy walking, golf, gardening, bowling, yoga, fishing, horseshoes, 
archery, etc. 
Times per week:     0   1   2   3   4   5   6   7   8   9   10   11  12   13   
14+ 
  
Moderate exercise (not exhausting):   
Fast walking, easy bicycling, tennis, easy swimming, badminton, 
dancing, volleyball, baseball, etc. 
Times per week:     0   1   2   3   4   5   6   7   8   9   10   11  12   13   
14+ 
Strenuous exercise activities (heart beats rapidly):   
Running, jogging, hockey, football, soccer, squash, basketball, cross 
country skiing, judo, roller skating, vigorous swimming, vigorous 
long distance bicycling, etc. 
Times per week:     0   1   2   3   4   5   6   7   8   9   10   11  12   13   
14+ 
 
14. Are you healthy and fit?              Yes        No           
             Comments:    
__________________________________________________________________
______ 
15.  How much alcohol do you drink? (average  #drinks  per week)  ___________ 
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16.  Do you have any food allergies?      Yes    No    
       If yes, explain: 
________________________________________________________________________
______ 
 
17. Do you follow a special diet?        Yes      No 
       If yes, explain:  
________________________________________________________________________
______ 
 
18.  Do you plan to change your diet in the next 8 weeks?      Yes     No 
       If yes, explain:  
________________________________________________________________________
______ 
 
19.  Do you plan to change your exercise level in the next 8 weeks?      Yes     No 
        If yes, explain:  
____________________________________________________________________
______ 
 
20.  Are you willing to consume vinegar supplements daily for 8 weeks?      Yes       No 
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Positive effects VIN: 
Helped her drink more water throughout the day 
Felt more refreshed, more balanced, body didn’t feel as gross 
Made her more conscious of what she is putting in her body 
More room in clothes 
Increase in bowel movements 
Negative effects VIN: 
Reflux if taken too late at night 
Nausea 
Had slight nausea and stomach pain right after taking it, lasted for ~20 minutes each time 
Had frequent bowel movements the first day taking it 
Stomach burned afterwards 
Nausea 
Front teeth felt eroded 
Sweat smelled like vinegar 
Nausea 
Positive effects CON: 
Felt as if she lost weight while still eating the same 
Felt less hungry after taking it 
Negative effects CON: 
Eyes felt tired after taking it 
Stomach became irritated if it was taken too early and/or too late 
Problems: 
 
 Never Occasionally Weekly Daily 
VIN 5 3 2 1 
CON 8 2 0 0 
 
Comments on problems: 
Hard to take with you if you have to go somewhere 
Felt sick after taking it 
Hard to fit into a busy day 
Hard to remember to take each day 
Timing is often a problem 
Hard to fit into schedule  
Tasted bad, had to psyche self into taking it 
 
 
 
 
 
 
 
 
